Bronchoscopy for bevacizumab-related hemoptysis

Lung Cancer. 2007 Jun;56(3):465-8. doi: 10.1016/j.lungcan.2007.01.022. Epub 2007 Mar 26.

Abstract

Bevacizumab is the first anti-angiogenic agent inhibiting vascular endothelial growth factor (VEGF) for treatment of patients suffering from cancer. Life-threatening hemoptysis is the most serious adverse effect of bevacizumab. The inhibition of VEGF is a possible mechanism involved in the destruction of normal lung tissue and subsequent hemoptysis. We report a case of bevacizumab-related hemoptysis and associated bronchoscopic findings that were successfully treated with rigid bronchoscopy and laser photocoagulation.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / secondary
  • Angiogenesis Inhibitors / adverse effects
  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Bronchoscopy / methods*
  • Diagnosis, Differential
  • Disease Progression
  • Follow-Up Studies
  • Hemoptysis / chemically induced
  • Hemoptysis / diagnosis*
  • Humans
  • Lymphatic Metastasis
  • Magnetic Resonance Imaging
  • Male
  • Mediastinum
  • Middle Aged
  • Neoplasms, Unknown Primary / diagnosis
  • Neoplasms, Unknown Primary / drug therapy*
  • Severity of Illness Index
  • Spinal Neoplasms / diagnosis
  • Spinal Neoplasms / drug therapy*
  • Spinal Neoplasms / secondary
  • Thoracic Vertebrae*
  • Vascular Endothelial Growth Factor A

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab